BioNTech SE (BNTX) short interest & options flow
NASDAQBNTX barely moved last week, down 0.2%, while closest peer MRNA rallied nearly 10% and the broader mRNA-adjacent group pushed higher across the board. The gap is sharpest when you line up the peer moves. Moderna gained close to 10% on the week. ARCT fell 15%, so the cohort is not uniformly bid, but BNTX's near-flat week looks distinctly muted against the…
BNTX downgraded by BMO Capital to Market Perform from Outperform, price target cut to $105 from $128 (-18%), now trading below revised PT at $103.76.
- Market cap
- $22.49B
- Next earnings
- 2 Mar 2027
Key data as of 5 Nov 2026

BNTX news and analysis
RSSNo long-form analysis yet for BNTX. Pulse alerts and the live data picture are available on ORTEX.
Open BNTX on ORTEX →Want the live picture for BNTX?
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for BNTX — free to start on ORTEX.
Sign up for free →Open BNTX on ORTEX